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Background/aim: The purpose of this study was to evaluate nosocomial infections occurring in our hospital intensive care units (ICUs)
and the risk factors for these, and to determine the effect of these infections on mortality and cost.
Materials and methods: This retrospective study was performed via infection control committee surveillance data, ICU records, and
information processing data between 1 January and 31 December 2013 at the Kanuni Education and Research Hospital.
Results: A total of 309 nosocomial infections were observed in 205 out of 566 patients. The density of nosocomial infections was 25.4 in
1000 patient days. Hospitalization was prolonged, and APACHE II and Charlson comorbidity scores were high in patients developing
nosocomial infections (P < 0.001). Of the patients diagnosed with a nosocomial infection, 170 died. Infections were determined as
the cause of death in 62 (36.5%) of the nonsurviving patients with a nosocomial infection. Acinetobacter baumannii was identified
in 46 (74.2%) of the patients that died from nosocomial infections. The mean cost in patients developing a nosocomial infection was
15,229.30 Turkish lira (TL), compared to 9648.00 TL in patients without a nosocomial infection (P = 0.002).
Conclusion: Regular infection control education sessions need to be held and the number of nurses needs to be increased in order to be
able to reduce this high mortality, morbidity, and cost.
Key words: Nosocomial infections, intensive care units, cost analysis

1. Introduction
Nosocomial infections are one of the world’s most
significant health problems, leading to prolongation of
hospitalization and increased morbidity, mortality, and
treatment costs. Nosocomial infections are most common
in intensive care units (ICUs). These are units intended
to treat patients requiring intensive care due to severe
function compromise in one or more organ systems. They
are furnished with high-tech equipment and are provided
with 24-h vital sign monitoring and patient care (1,2).
The purpose of this study was to evaluate nosocomial
infections occurring in our hospital ICUs and the risk
factors for these, and to determine the effect of these
infections on mortality and cost.
2. Materials and methods
2.1. Study design
The study was performed retrospectively at the Kanuni
Education and Research Hospital, Turkey, which has
* Correspondence: gurdalyilmaz53@hotmail.com

a 605-bed capacity, including 46 adult ICU beds. Our
hospital contains four adult ICUs (Anesthesia and
Reanimation, Surgical, Medical, and Neurology). Due
to nurse shortages, the nurse/patient ratio in our ICUs
ranges between 1:3 and 1:4, and may even rise to 1:6 on
some nights. The physical criteria also do not meet the
recommended criteria. The patients hospitalized in the
ICUs for more than 2 days between 1 January and 31
December 2013 were enrolled in the study. Each patient’s
medical file, infection control committee surveillance
data, ICU records, pharmacy records, and information
processing data were used. Patients were divided into two
groups: those developing nosocomial infections (Group A)
and those not developing nosocomial infections (Group
B). The diagnosis of nosocomial infection was based on
the Centers for Disease Control and Prevention criteria
(3). Nosocomial infection density was calculated via the
formula [(number of nosocomial infections/patient days)
× 1000]. Device-associated infection rate (DAIR) was
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calculated via the formula [(number of device-associated
infections/device-days) × 1000]. Device utilization (DU)
was calculated via the formula (number of device days/
patient days).
The Acute Physiology and Chronic Health Evaluation
(APACHE) II scores used were those calculated within
the first 24 h of hospitalization (4). Charlson comorbidity
index scores were obtained through the examination
of all patients’ medical records (5). The identification
of microorganisms and testing for antimicrobial
susceptibility were conducted via the Phoenix system
(Becton Dickinson), the disk diffusion test, and classic
methods. Polymicrobial infection was defined as the
presence of two or more agent microorganisms.
Cost in the study was based on the cost of treatment
to the patient (invoice cost). Cost for each patient was
obtained from our hospital’s information processing center
data. Invoices were examined in detail, and comparisons
were made by calculating patients’ treatment costs. In
performing these comparisons, costs were divided into
five groups: drug costs, expendable supplies costs, medical
services costs (laboratory test charges, surgery charges,
blood center charges, and consultation charges), other
costs, and total costs. When the total cost was determined,
this was also calculated in terms of Euros and US dollars
based on that day’s exchange rate. Physician, nurse, and care
attendant charges were not included in cost calculations.
2.2. Statistical analysis
Descriptive statistical analysis was performed for all
parameters. The Kolmogorov–Smirnov test was used to
determine eligibility of variables. The data in conformity
with normal distribution were analyzed using Student’s
t-test, and those not conforming to normal distribution
were analyzed using the Mann–Whitney U test. The
data obtained by measurements are given as mean ±
standard deviation. The data obtained by counting are
given as number (%); analyses were performed using the
chi-square test. In addition, multivariate analyses were
performed using logistic regression. The results of the
analysis are presented as P-values, odds ratio (OR), and
95% confidence interval (95% CI). P < 0.05 was regarded
as significant.
3. Results
A total of 810 patients were hospitalized and treated in our
hospital’s adult ICUs in 2013, 566 being hospitalized in the
ICUs for more than 2 days. Of these patients, 310 patients
were male and 255 female, with a mean age of 69.6 ± 17.7
years. The mean duration of hospitalization was 21.5 ± 24.3
days. The Charlson comorbidity index score was 3.0 ± 1.9
and the APACHE II score 19.1 ± 3.1. The urinary catheter
(UC) use rate was 0.89%, central venous catheter (CVC) use
rate 0.64%, and mechanical ventilator (MV) use rate 0.56.
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Furthermore, 309 nosocomial infections were observed in
205 of the 566 patients. Nosocomial infection density was
25.4 in 1000 patient days. One hundred thirty-two (42.7%)
of the nosocomial infections were primary bacteremia
(101 catheter-related blood stream infections (CR-BSIs)),
86 (27.8%) were pneumonia (73 ventilator-associated
pneumonia (VAP) cases), 48 (15.5%) were urinary tract
infections (UTIs) (all of the infections were UTI related
to urinary catheter (UC-UTI)), 24 (7.8%) were surgical
site infections, 16 were soft tissue infections, and 3 were
central nervous system infections. Hospitalization was
prolonged and APACHE II and the Charlson comorbidity
scores were high in patients developing nosocomial
infection (P < 0.001). The incidence of nosocomial
infection was 1.73 times higher in patients with APACHE
II scores above 20 (P = 0.002). Nosocomial infections were
more common in patients with trauma, cerebrovascular
disease, diabetes mellitus, and kidney diseases (P < 0.05).
Days of MV, CVC, and UC use were higher in patients
developing nosocomial infections (P < 0.001). Lower
rates of infection occurred in patients receiving enteral
nutrition and were higher in patients undergoing surgery,
receiving parenteral nutrition, and using vasopressors
(P < 0.05). The demographic and clinical characteristics
of patients with or without nosocomial infection in the
ICUs are shown in Table 1. In multivariable analysis, a
high Charlson comorbidity index score (OR: 1.82), length
of hospitalization (OR: 1.26), and presence of diabetes
mellitus (OR: 2.43) were determined to be risk factors for
nosocomial infections (Table 2).
Of the 309 nosocomial infections observed in our
hospital ICUs, 224 gram-negative microorganisms, 83
gram-positive microorganisms, and 24 Candida spp.
were identified as agents (Table 3). Polymicrobial agents
were identified in 35 nosocomial infections, while no
agent could be identified in 18 infections. The most
common agents were Acinetobacter baumannii (n = 72),
Pseudomonas aeruginosa (n = 57), and Staphylococcus
aureus (n = 51). Carbapenem resistance was present in 66
(91.7%) A. baumannii cases, while no colistin resistance
was observed. While no piperacillin/tazobactam or
amikacin resistance was observed in P. aeruginosa cases,
resistance to carbapenems was identified in 21 (42.1) cases.
Extended spectrum beta-lactamase (ESBL) was positive in
all K. pneumoniae, but not in two E.coli cases. The most
effective antibiotics for E.coli and K. pneumoniae were
carbapenems and amikacin. Methicillin resistance was
determined in 23 (45.1%) of S. aureus cases and all cases
of coagulase-negative staphylococci (CNS). Vancomycin
resistance was present with one Enterococcus strain.
In this study, 36.7% of patients hospitalized in the
ICU for more than 2 days died within 7 days, 16.8% in
8–14 days, 15.5% in 15–30 days, and 10.8% in more than
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Table 1. The demographic and clinical characteristics of patients with or without nosocomial infection in the ICUs.
Characteristics

Group A
n = 205

Group B
n = 361

Age

70.3 ± 16.7

69.2 ± 18.3

Sex (male)

118 (57.6%)

192 (53.2%)

APACHE II

19.9 ± 3.5

18.4 ± 2.5

APACHE II >15

196

OR (95% CI)

P
0.654

1.19 (0.83–1.71)

0.315

338

1.48 (0.64–3.53)

0.429

1.73 (1.20–2.49)

0.002

<0.001

APACHE II >20

98

125

Length of hospitalization

28.1 ± 32.4

17.8 ± 17.1

<0.001

Charlson comorbidity index

3.2 ± 1.4

2.9 ± 2.1

<0.001

Trauma

27

18

2.89 (1.49–5.64)

0.0005

Cardiac disease

7

12

1.03 (0.36–2.86)

0.853

Primary and underlying diseases

Cerebrovascular disease

45

51

1.71 (1.07–2.73)

0.017

Abdominal disease

25

31

1.48 (0.82–2.67)

0.167

Diabetes mellitus

59

33

4.02 (2.45–6.20)

<0.001

Kidney disease

42

48

1.68 (1.04–2.71)

0.025

Malignity

17

44

0.65 (0.35–1.21)

0.195

Other disease

42

78

0.93 (0.60–1.45)

0.754

1.30 (0.80–2.11)

0.261

Invasive procedures
Endotracheal intubation

173

291

Ventilator days

18.5 ± 16.0

9.8 ± 11.3

Central venous catheter

192

315

Central venous catheter days

21.3 ± 14.7

11.6 ± 7.4

Urinary catheter

193

326

<0.001
2.16 (1.09–4.32)

0.024

1.73 (0.84–3.61)

0.152

<0.001

Urinary catheter days

25.8 ± 21.3

13.9 ± 10.5

Nasogastric catheter

89

154

1.03 (0.72–1.48)

0.861

<0.001

Enteral nutrition

152

316

0.41 (0.26–0.65)

<0.001

Surgery

61

76

1.59 (1.05–2.40)

0.020

97

85

2.92 (1.99–4.28)

<0.001

Medication
Total parenteral nutrition
Steroids

36

53

1.24 (0.76–2.02)

0.367

Vasopressor

114

167

1.46 (1.02–2.08)

0.033

Mortality

170

282

1.36 (0.86–2.17)

0.170

30 days. One hundred seventy patients diagnosed with
nosocomial infection died. Infections were identified as
the cause of death in 62 (36.5%) of the fatal patients with a
nosocomial infection. The patients had died before culture
growth was reported in 21 (33.9%) of these infections.
Empiric treatment-resistant bacterial growth was present
in 17 (27.4%) patients that started on such treatment.
Treatment was commenced after 3.5 ± 1.1 days in 11
(17.7%) patients. Mortality occurred despite appropriate
treatment in 13 (21%). The agent microorganism was A.

baumannii in 46 (74.2%) of the patients that died due to
nosocomial infection.
The mean cost for patients developing nosocomial
infections was 15,229.3 ± 23,280.9 Turkish lira (TL),
compared to 9648.0 ± 12,031.9 TL for patients without
nosocomial infection (P = 0.002) (Table 4). Medical service
expenses constituted the highest cost. Medical service costs
in patients with nosocomial infections were on average
5000 TL higher than those in patients without nosocomial
infection (P = 0.001). Laboratory test charges represented
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Table 2. Risk factors of nosocomial infection (multivariate analysis).
Risk factors

P

OR

95% CI

Charlson comorbidity index

0.014

1.82

1.12–2.98

Length of hospitalization

0.026

1.26

1.10–2.32

Trauma

0.152

3.62

0.82–9.24

Diabetes mellitus

0.020

2.43

1.14–4.10

Total parenteral nutrition

0.218

1.36

0.53–3.92

Table 3. Microorganism agents identified in nosocomial infections in our hospital ICUs.

Microorganism

Primary bacteremia
(n = 132)

Pneumonia
(n = 86)

UTI
(n = 48)

Other
(n = 43)

149

83

48

51

Gram-negative microorganisms

96

66

37

25

Escherichia coli

11

4

11

8

Acinetobacter baumannii

32

29

4

7

Klebsiella spp.

10

5

8

2

Pseudomonas aeruginosa

23

21

6

7

Serratia marcescens

8

2

1

0

Enterobacter spp.

4

3

2

0

Stenotrophomonas maltophilia

4

2

0

0

Proteus mirabilis

3

0

5

1

Burkholderia cepacia

1

0

0

0

Gram-positive microorganisms

40

16

5

22

Staphylococcus aureus

24

16

0

11

CNS

9

0

0

4

Enterococcus spp.

7

0

5

7

Fungi

13

1

6

4

Candida albicans

1

1

2

1

Candida spp.

12

0

4

3

a considerable part of these high costs. The second highest
cost component was drug costs. Antibiotics represented a
considerable part of the drug costs. Microorganisms being
resistant did not affect patients’ total costs (P = 0.178).
However, while the costs in patients developing infections
with resistant microorganisms without mortality in the first
3 days were 21,750 ± 24,676 TL, the costs for patients with
sensitive microorganism infection were 12,556 ± 16,547
TL (P < 0.001). The costs of patients developing more than
one infection were 24,876 ± 32,738 TL, compared to the
costs of 9652 ± 12,496 TL for those with one infection (P
< 0.001).
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4. Discussion
The type, rate, and agents of nosocomial infections may
vary from country to country, hospital to hospital, and
unit to unit. These infections are most frequently seen in
hospital ICUs. The nosocomial infection rate determined
in ICUs is generally 5–10 times higher than the general
nosocomial rate. ICU type, length of hospitalization,
underlying diseases, severity of disease, and invasive
procedures performed play a significant role in high
infection rates (6). The National Nosocomial Infections
Surveillance (NNIS) report cited an infection rate of 18.7
per 1000 patient days (7). One multicenter study in Turkey
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Table 4. Costs of patient with or without nosocomial infection developing in the ICUs.
Costs

Group A
n = 205

Group B
n = 361

P

Drug costs

3495 ± 4475

2232 ± 3324

<0.001

Expendable supplies costs

1022 ± 1463

571 ± 834

0.001

Medical services costs

13060 ± 20,691

7823 ± 10,284

0.001

Other costs

834 ± 345

761 ± 356

0.286

Mean costs (TL)

15229 ± 23,281

9648 ± 12,032

0.002

Mean costs (dollars)

5439 ± 8315

3446 ± 4297

0.002

Mean costs (Euros)

5060 ± 7735

3205 ± 3997

0.002

1 US dollar = 2.80 TL, 1 Euro = 3.01 TL.

reported a nosocomial infection rate of 33.9 per 1000
patient days (8). The rate of nosocomial infection in our
study was 41.2 per 1000 patient days.
The most prevalent type of infection was pneumonia,
with rates of 20%–47%, followed by UTIs and primary
bloodstream infection (BSIs) (6,7,9). Esen and
Leblebicioglu performed a one-day point prevalence study
of ICUs in Turkey in which they observed that pneumonia
and lower respiratory tract infection (28.0%), laboratoryconfirmed BSI (23.3%), and UTI (15.7%) were the most
frequent types (10). In this study, primary BSI was the
most common (42.7%) nosocomial infection, followed
by pneumonia (27.8%), UTI (15.5%), and surgical site
infection (SSI) (7.8%). The majority of these infections in
ICUs are linked to the use of invasive devices. One analysis
of NNIS Medical-Surgery ICU data reported that 83% of
nosocomial infections, 87% of primary BSIs, and 97% of
UTIs were linked to the use of invasive devices (7). In our
study, all UTIs, 84.9% of pneumonia cases, and 58.3% of
BSIs were linked to the use of invasive devices. Our UC and
MV use levels were above the 90th percentile according
to National Healthcare Safety Network (NHSN) data
(11), while CVC and MV use level was close to the 75th
percentile. Compared to INICC data (12) and the 2013
report of the National Hospital Infections Surveillance
Network (UHESA) in Turkey (13), the UC use rate was
compatible with the 75th percentile, and the CVC use and
MV use level with compatible with the 50th percentile.

The rate of CR-BSIs was 9.9 per 1000 CVC days, compared
to 1.8 in the NHSN 75th percentile, 11.7 in the INICC
50th percentile, and 6.9 in the UHESA 75th percentile.
The rate of UC-UTIs was 4.4 per 1000 urinary catheter
days, compared to 5.2 in the NHSN 90th percentile, 9.1
in the INICC 75th percentile, and 5.3 in the UHESA 75th
percentile. The rate of VAP was 10.7 per 1000 ventilator
days, 3.9 in the NHSN 90th percentile, 16.5% in the INICC
50th percentile, and 11.9 in the UHESA 50th percentile.
These findings show that VAP and CVC-associated BSI
rates in our hospital ICUs are high on the basis of the
NHSN data and low according to the data from the INICC
(Table 5).
Many different risk factors for nosocomial infections,
such as a high APACHE II score, lengthy hospitalization,
long-term use of invasive devices, total parenteral nutrition,
and presence of a comorbid disease, have been reported
in the literature (14,15). Vasopressor use contributes to
microorganisms’ biofilm production, and this plays a
significant role in nosocomial infections (16). In terms
of the causes of the high infection rate in our study, high
APACHE II and Charlson comorbidity index scores (P <
0.001), lengthy hospitalization (P < 0.001), long-term use
of invasive devices (P < 0.001), surgery (P = 0.02), total
parenteral nutrition (P < 0.001), and vasopressin use (P
= 0.033) were more frequent in patients developing an
infection. Other adverse factors such as a high number
of patients per nurse in ICUs, the lack of isolation rooms,

Table 5. Comparison of invasive device-associated nosocomial infections.
Our study’s
rate

UHESA
rate (percentile)

INICC
rate (percentile)

NNIS
rate (percentile)

CR-BSI

9.9

6.9 (75th)

11.7 (50th)

1.8 (75th)

UC-UTI

4.4

5.3 (75th)

9.1 (75th)

5.2 (90th)

VAP

10.7

11.9 (50th)

16.5 (50th)

3.9 (90th)
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the low surface area available per bed, and a distance of
less than 2 m between beds may also be other reasons
for the high level of nosocomial infections. We found
that a high Charlson comorbidity index score, prolonged
hospitalization, and diabetes mellitus were independent
risk factors for nosocomial infections in the multivariable
model.
The primary diseases of patients in ICUs, accompanying
comorbid conditions and nosocomial infections, affect
mortality. Raffin reported that the most important causes
of mortality in ICUs are hospital-acquired infections,
arrhythmias, kidney failure, liver failure, and heart failure
(17). Mortality attributable to nosocomial infections being
determined in 36.5% of the fatal patients with nosocomial
infections shows the significance of these infections.
Delayed culture results in these infections and the resulting
rise in mortality due to delays in effective treatment also
reveal the need for rapid diagnostic techniques.
The distribution of nosocomial infection agents
according to infection type may vary among hospitals or
countries. Some pathogens are determined more frequently
in some hospitals, and this is helpful in empiric treatment.
A multicenter study conducted in Turkey reported P.
aeruginosa (20.8%), S. aureus (18.2%), Acinetobacter spp.
(18.2%), and Klebsiella spp. (16.1%) as agents (10). The
most commonly encountered microorganisms in a study
from Italy were A. baumannii (61.9%), P. aeruginosa
(22.5%), E. faecalis (4.2%), and C. albicans (4.2%) (18).
The most common microorganisms in a study from Egypt
were Acinetobacter species (21.8%) and Klebsiella species
(18.4%), and all Acinetobacter strains were multidrugresistant (19). The most common agents in our study were
A. baumannii, P. aeruginosa, and S. aureus.
The most important problem in the treatment of A.
baumannii infection, the levels of which are increasing in
the literature, is that almost all strains exhibit resistance
to many antibiotics, including carbapenems, leading to a
reduction in antibiotic alternatives for use in treatment
(20). Akın et al. showed imipenem resistance in A.
baumannii at a level of 42% in 2004 but of 92% by 2008
(21). Although levels of resistance to antibiotics vary in all
centers, the high level of multiresistant strains is worrying.
Infections of pan-resistant origins have been reported
in recent years (22). Carbapenem resistance was present
in 91.7% of A. baumannii strains in this study. Mortality
occurred in 63.9% of A. baumannii infections. Karabay et
al. reported mortality in 77% of A. baumannii infections
(23).
The increase in carbapenem resistance in Turkey, as
in many other countries, in recent years has resulted in
colistin, the use of which was restricted for many years
due to its side-effects, becoming an important treatment
option. Studies have reported that colistin cannot be used
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alone, but only together with another antibiotic (24).
Patient costs in ICUs were considerably higher
for patients developing nosocomial infections than
those without infections. The cost of medical services
represented the most significant part of that high cost.
Medical service costs were higher for patients with
nosocomial infections than those without. The cost of
laboratory tests constituted the highest proportion of
medical service costs. Drug costs represent a significant
part of the additional expenses caused by nosocomial
infections. Antibiotics represent a significant part of drug
costs. Some studies have reported that antibiotic expenses
constitute half of all costs, while others have reported
that additional hospitalization time is the most important
contributor to nosocomial infection costs (25,26). Yalçın et
al. reported an additional antibiotic cost of $1136 (25). The
development of resistance to antibiotics is also emerging
as a significant problem. High mortality and morbidity in
infections from resistant microorganisms are problematic.
It is particularly noteworthy that costs in infections from
resistant microorganisms without mortality during the
first 3 days are very high. One study from the United
States assessed the costs of antibiotics used in sensitive and
resistant gram-negative cases and reported high antibiotic
costs in resistant microorganisms (27).
The additional costs and deaths resulting from
nosocomial infections clearly reveal the need for priority
to be given to activities aimed at controlling these
infections. The SENIC Project, which demonstrated
that nosocomial infections decrease by 32% in hospitals
applying infection control programs, represents a solid
basis for determination to prevent infections worldwide
(28). Yilmaz et al. reported that a 41.7% decrease in
intravascular catheter infections was achieved through
infection control training (15). Within that context, it will
be useful for all health professionals and patients to be
made aware of infection control procedures and rational
drug use through the arrangement of in-service training
programs, which all physicians in a hospital should attend.
Savings resulting from the prevention of nosocomial
infections are incomparably higher than spending on
infection control procedures. The total cost of nosocomial
infections as of 2001 in the United States was $5 billion,
whereas infection control costs correspond to only 16%
of this (29). In one study from Great Britain, gel-form
antiseptic containing alcohol was placed by every bedside,
the total cost being 5000 pounds sterling. Following the
use of the antiseptic, a significant decrease was observed
in the incidence of diarrhea caused by hospital-acquired
methylene-resistant S. aureus (MRSA) and C. difficile. The
study reported a savings of approximately 208,000 pounds
(30). All these studies show that intense work is needed
with all sides taking an active part in infection control
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procedures in order to reduce nosocomial infection rates
and to achieve lower mortality and costs.
In conclusion, as shown by the Charlson comorbidity
index and APACHE II scores, serious illnesses are being
caused in ICUs. The number of invasive procedures
performed on these patients is also therefore very high.
The high patient/nurse ratio represents a significant
problem. This is a cause of numerous complications, and

particularly infections. Nosocomial infections prolong
hospitalization times and increase costs. The fact that
nosocomial infections can be prevented with an increase
in compliance with infection control procedures is
important in terms both of morbidity and mortality and of
costs. Regular infection control procedure seminars need
to be held in Turkish hospitals, and the number of nurses
needs to be increased.
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